Pyoderma gangrenosum
Pyoderma gangrenosum je rijetka, upalna kožna bolest u kojoj bolne pustule ili čvorići pretvaraju se u čireve koji progresivno rastu. Pyoderma gangrenosum nije zarazan. Liječenje može uključivati kortikosteroide, ciklosporin ili različita monoklonska protutijela. Iako može zahvatiti osobe bilo koje dobi, najčešće pogađa ljude u 40‑im i 50‑im godinama.
☆ U rezultatima Stiftung Warentest iz Njemačke za 2022., zadovoljstvo potrošača s ModelDermom bilo je samo malo niže nego s plaćenim konzultacijama o telemedicini.
Na nozi osobe s ulceroznim kolitisom.
relevance score : -100.0%
ReferencesPyoderma gangrenosum je rijetko stanje kože koje uzrokuje bolne čireve s crvenim ili ljubičastim rubovima. Klasificira se kao upalna bolest i dio je skupine koja se naziva neutrofilne dermatoze. Uzrok Pyoderma gangrenosum je složen i uključuje probleme s urođenim i adaptivnim imunitetom kod osoba koje su genetski predisponirane. Nedavno su istraživači usredotočili svoju pažnju na folikul dlake kao potencijalnu početnu točku bolesti.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum je rijetko kožno stanje koje uzrokuje izrazito bolne čireve. Iako uzrok još nije u potpunosti razjašnjen, poznato je da uključuje povećanu aktivnost određenih imunoloških stanica. Liječenje bolesti još uvijek nije jednostavno. Dostupni su razni lijekovi koji suzbijaju imunološki sustav ili modificiraju njegovu aktivnost. Uz to, pažnja je usmjerena i na liječenje rana te upravljanje boli. Kortikosteroidi i ciklosporin često su prvi izbor, ali u posljednje vrijeme sve više istraživanja usmjerava se na biološke terapije, poput inhibitora TNF‑α. Ovi biološki lijekovi pokazuju sve veću prednost, osobito kod pacijenata s drugim upalnim stanjima, i primjenjuju se i u ranijim fazama bolesti.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
